Madrigal Pharmaceuticals
Madrigal Pharmaceuticals is a biopharmaceutical company focused on delivering novel treatments for metabolic dysfunction‑associated steatohepatitis (MASH), formerly known as NASH.
It is the developer of the first FDA‑approved therapy for adults with moderate to advanced liver fibrosis.
Address: 200 Barr Harbor Drive, Suite 200, West Conshohocken, PA 19428
Phone: (267) 327‑4445
-
West Conshohocken’s Madrigal Pharmaceuticals Eyes $1B Expansion Deal
Madrigal Pharmaceuticals is making another major move in the rapidly growing liver disease treatment market, writes John George for The…
-
Madrigal’s Rezdiffra Nears Blockbuster Status With $958M in First Full Year on Market
In its first full year on the market, West Conshohocken-based Madrigal Pharmaceuticals’ flagship drug Rezdiffra nearly got to blockbuster status,…
-
Conshohocken’s Madrigal Makes $4B Bet on the Future of Liver Disease Treatment
Conshohocken’s Madrigal Pharmaceuticals is making a major move that could reshape the future of liver disease treatment, writes John George…
-
Madrigal Pharmaceuticals Expands As Breakthrough Drug Fuels Growth
West Conshohocken’s Madrigal Pharmaceuticals is relocating its headquarters to accommodate rapid expansion, reports John George for The Philadelphia Business Journal.…
-
West Conshohocken’s Madrigal Pharmaceuticals Gets FDA Green Light
West Conshohocken’s Madrigal Pharmaceuticals earned a major win with the FDA approval of its first commercial product, reports John George…
-
Upper Providence’s GSK Bets Big on ‘Game-Changing’ Liver Disease Drug
GSK has announced a $1.2 billion deal to acquire efimosfermin alfa from Boston Pharmaceuticals, writes John George for the Philadelphia…
-
Check Out the Highest Paid CEOs of the Philadelphia Area
Last year was a big one for Philadelphia area CEOs. Ten of the top twelve highest earners saw an increase…
-
Conshohocken’s Madrigal Pharmaceuticals Reports Sales Through the Roof
Conshohocken’s Madrigal Pharmaceuticals, saw third-quarter sales soar for its NASH treatment, Rezdiffra, writes John George for the Philadelphia Business Journal.…
-
Madrigal Pharmaceuticals in Conshohocken Reports $14.6 Million in Sales from Groundbreaking NASH Drug Rezdiffra
Conshohocken-based Madrigal Pharmaceuticals generated $14.6 million in sales from Rezdiffra, its first and flagship product, during the second quarter of…
-
Conshohocken-based Madrigal Pharmaceuticals Launches Groundbreaking NASH Drug, Rezdiffra
In the less than two months since becoming the first drug developer to receive Food and Drug Administration clearance for…
-
Madrigal Pharmaceuticals First to Receive FDA Clearance for a NASH Treatment
Madrigal Pharmaceuticals has been given Food and Drug Administration market clearance for its experimental treatment for NASH, a fatty liver…
-
Madrigal Pharmaceuticals Sells $500M in Stocks in Prep for FDA Approval
Conshohocken-based Madrigal Pharmaceuticals is in a flurry of activity as it prepares for the potential launch of its NASH drug…
-
Madrigal Pharmaceuticals Plans $500 Million Stock Offering While Awaiting Nod from FDA
Conshohocken-based Madrigal Pharmaceuticals plans to raise $500 million while anticipating FDA approval of a groundbreaking therapy, writes John George for…
-
Former Sanofi Executive Named CEO of Conshohocken-based Madrigal Pharmaceuticals
Conshohocken biopharmaceutical company Madrigal Pharmaceuticals has named Bill Sibold as the new CEO taking over from Dr. Paul Friedman. He…
-
Montgomery County Pharma Company Aims to Have First FDA-Approved Drug for This Silent Disease
Currently there is no U.S. Food and Drug Administration-approved medicine for nonalcoholic steatohepatitis, also referred to as NASH. NASH is…
-
West Conshohocken Is Home to One of Best-paying Biopharma Companies in Country
One Montgomery County company found its place on the list of seven best-paying biopharma companies in the nation where workers…
-
Conshohocken-based Madrigal Pharmaceuticals’ Shares Skyrocket Following Liver Disease Clinical Trial
Conshohocken-based Madrigal Pharmaceuticals saw its shares leap in value after the company reported additional positive late-stage clinical trial data for…
-
Madrigal Pharmaceuticals seeks to raise $125M
Madrigal Pharmaceuticals Inc., a Montgomery County biopharmaceutical company, is seeking to raise $125 million through a common stock offering that began…
Founding Partners
Advertisement
Affiliate Partners
Community Partners
